| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/08/2013 | US20130202612 Compositions and methods for treating bone conditions |
| 08/08/2013 | US20130202610 Methods of treating psoriasis using il-17 antagonists |
| 08/08/2013 | US20130202606 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same |
| 08/08/2013 | US20130202604 Therapeutic Uses of Monoclonal Antibodies to the Angiotensin-II Type-1 Receptor |
| 08/08/2013 | US20130202603 BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF |
| 08/08/2013 | US20130202602 Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| 08/08/2013 | US20130202601 Assays, methods and kits for predicting renal disease and personalized treatment strategies |
| 08/08/2013 | US20130202595 Factor IX Polypeptides and Methods of Use Thereof |
| 08/08/2013 | US20130202594 ALK1 Antagonists and Their Uses in Treating Renal Cell Carcinoma |
| 08/08/2013 | US20130202590 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| 08/08/2013 | US20130202589 Diagnosis and treatment of autoantibody-mediated heart disease |
| 08/08/2013 | US20130202588 Antitumor T Cell Response Enhancer |
| 08/08/2013 | US20130202586 Stem cell therapy using inhibitors of lysophosphatidic acid |
| 08/08/2013 | US20130202585 Stabilising formulation for immunoglobulin g compositions in liquid form and in lyophilised form |
| 08/08/2013 | US20130202584 Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8 |
| 08/08/2013 | US20130202554 Compositions and methods that enhance an immune response |
| 08/08/2013 | US20130202552 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins |
| 08/08/2013 | US20130202528 Differential gene expression in physiological and pathological angiogenesis |
| 08/08/2013 | US20130199519 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 08/08/2013 | CA2861415A1 Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates |
| 08/08/2013 | CA2861402A1 Stabilized aqueous antibody compositions |
| 08/08/2013 | CA2856618A1 Negatively charged nucleic acid comprising complexes for immunostimulation |
| 08/08/2013 | CA2856615A1 Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or pepide antigen |
| 08/08/2013 | CA2848985A1 C10rf32 antibodies, and uses thereof for treatment of cancer |
| 08/07/2013 | EP2623594A1 Antibody against human prostaglandin e2 receptor ep4 |
| 08/07/2013 | EP2623592A1 Antihuman ccr7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier |
| 08/07/2013 | EP2623516A2 Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R |
| 08/07/2013 | EP2623515A1 ANTI TNFalpha HUMANIZED ANTIBODY AND FRAGMENT ANTIGEN BINDING (FAB) AND USE THEREOF |
| 08/07/2013 | EP2623125A1 Elimination of immune responses to viral vectors |
| 08/07/2013 | EP2623124A1 Elimination of immune responses to viral vectors |
| 08/07/2013 | EP2623119A1 Glioma treatment method, glioma examination method, method of delivering a desired material to a glioma, and drug used in said methods |
| 08/07/2013 | EP2623118A1 Mucosal adjuvant composition |
| 08/07/2013 | EP2623117A1 Immunogenic nanomedicine composition and preparation and uses thereof |
| 08/07/2013 | EP2623116A1 A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response |
| 08/07/2013 | EP2623115A1 Immunogenic control of tumours and tumour cells |
| 08/07/2013 | EP2623114A1 Vaccine composition for controlling ectoparasite infestations |
| 08/07/2013 | EP2623110A1 Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| 08/07/2013 | EP2622101A2 Genetic variations in the interleukin-6 receptor gene as predictors of the response of patients to treatment with interleukin-6 receptor inhibitors |
| 08/07/2013 | EP2622082A1 Generation of virosome particles |
| 08/07/2013 | EP2622078A1 Fusion protein for secretory protein expression |
| 08/07/2013 | EP2622066A1 Production of low fucose antibodies in h4-ii-e rat cells |
| 08/07/2013 | EP2621955A1 Anti-ceacam6 antibodies and uses thereof |
| 08/07/2013 | EP2621954A1 Anti-rori antibodies |
| 08/07/2013 | EP2621951A1 Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis |
| 08/07/2013 | EP2621949A1 Polypeptides that bind to human complement component c5 |
| 08/07/2013 | EP2621534A2 Selective removal of age-modified cells for treatment of ather0sclerosis |
| 08/07/2013 | EP2621533A2 Antibody compositions and methods of use |
| 08/07/2013 | EP2621532A1 Generation, characterization and uses thereof of anti-her3 antibodies |
| 08/07/2013 | EP2621531A1 Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
| 08/07/2013 | EP2621530A2 Improved adjuvant system for vaccine administration |
| 08/07/2013 | EP2621529A2 Viral vector immunogenic compositions |
| 08/07/2013 | EP2621528A1 Vaccine |
| 08/07/2013 | EP2621527A2 The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals |
| 08/07/2013 | EP2621526A1 Antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| 08/07/2013 | EP2621525A2 Flavivirus domain iii vaccine |
| 08/07/2013 | EP2621524A1 Improved vaccine compositions |
| 08/07/2013 | EP2621523A1 Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| 08/07/2013 | EP2621522A2 Combined antigen and dna vaccine for preventing and treating autoimmune diseases |
| 08/07/2013 | EP2621511A1 Methods and pharmaceutical compositions for the treatment of bone density related diseases |
| 08/07/2013 | EP2621510A2 Anticancer agent |
| 08/07/2013 | EP2621291A1 Fat composition for programming immune response |
| 08/07/2013 | EP2621282A2 Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| 08/07/2013 | CN103237812A Anti-ephrin-B2 antibody and use thereof |
| 08/07/2013 | CN103237811A Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LPR6) multivalent antibodies |
| 08/07/2013 | CN103237810A Anti-angiogenesis therapy for the treatment of ovarian cancer |
| 08/07/2013 | CN103237807A Clostridium difficile antigens |
| 08/07/2013 | CN103237560A Cytomegalovirus GB antigen |
| 08/07/2013 | CN103237559A Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres |
| 08/07/2013 | CN103237443A Animal model for the evaluation of the efficacy of an HIV vaccine |
| 08/07/2013 | CN103233011A Application of PEG (polyethylene glycol)-PLA (Poly Lactic Acid) nano-material-coated HBV (Hepatitis B Virus)-CpG (Cytosine Phosphate Guanosine) in prevention and/or treatment of hepatitis B |
| 08/07/2013 | CN103232976A Medium supplement for virus production |
| 08/07/2013 | CN103232974A Hybridoma cell strain secreting high-neutralization activity infectious bursal disease virus (IBDV) monoclonal antibody |
| 08/07/2013 | CN103232541A Monoclonal antibodies against activated protein c |
| 08/07/2013 | CN103232540A Domain antibody construct |
| 08/07/2013 | CN103232539A Antibodies to opgl |
| 08/07/2013 | CN103230600A HBx-modified liver-cancer-inhibiting whole-cell vaccine, and preparation method and application thereof |
| 08/07/2013 | CN103230591A Medicament for treating liver cancer and application of JARID2 monoclonal antibody |
| 08/07/2013 | CN103230590A Interleukin-1 conjugates and uses thereof |
| 08/07/2013 | CN103230374A Inactivated vaccine producing and using method |
| 08/07/2013 | CN102552898B Purification preparation method of human rotavirus inactivated vaccines by utilizing ion exchange chromatography |
| 08/07/2013 | CN102443594B Receptor activator of nuclear factor kappa B ligand (RANKL)-HBaAg expression constructing object, yeast, manufacture method as well as application |
| 08/07/2013 | CN102380094B Application of specific polypeptide to preparation of rabies vaccine |
| 08/07/2013 | CN102344916B 类风湿关节炎特异性抗原 Rheumatoid arthritis-specific antigen |
| 08/07/2013 | CN102178948B Genetic engineering drug for treating and/or preventing cervical cancer |
| 08/07/2013 | CN102091329B Preparation method of inactivated porcine parvovirus vaccine and product thereof |
| 08/07/2013 | CN101845438B Sensitive diagnosis and relative treatment for cancers through 20 tumor specific related genes and products |
| 08/07/2013 | CN101798565B Bacillus anthracis capable of showing PA20 protein on surface of spore and application thereof |
| 08/07/2013 | CN101600455B Prophylactic tuberculosis vaccine |
| 08/07/2013 | CN101553506B Lingo binding molecules and pharmaceutical use thereof |
| 08/07/2013 | CN101450215B Polylactic acid-glycolic acid co-polymer nanometer granule with immunotoxin out-connection antibody inside |
| 08/07/2013 | CN101415820B Production of biologically active proteins |
| 08/07/2013 | CN101395183B Anti-ephb4 antibodies and methods using same |
| 08/07/2013 | CN101381681B Improved methods for producing oocysts |
| 08/07/2013 | CN101379089B Anti-ilt7 antibody |
| 08/07/2013 | CN101378781B Compositions and methods for production of immunoglobulins |
| 08/07/2013 | CN101312989B Monoclonal antibodies against claudin-18 for treatment of cancer |
| 08/06/2013 | US8502014 Method for the production of a single heavy chain antibody |
| 08/06/2013 | US8501926 Malaria vaccine |
| 08/06/2013 | US8501921 Detection of target analytes using particles and electrodes |
| 08/06/2013 | US8501917 Anti c-Met antibody and uses thereof |